Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Show more
Location: Mailpoint 810, South Block, Southampton, SO16 6YD, United Kingdom | Website: https://www.synairgen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
220.5K
52 Wk Range
$0.00 - $0.07
Previous Close
$0.00
Open
$0.00
Volume
N/A
Day Range
$0.00 - $0.00
Enterprise Value
-11.36M
Cash
4.554M
Avg Qtr Burn
-11.96M
Insider Ownership
0.57%
Institutional Own.
87.22%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SG016 / SNG001 Details COVID-19 | Phase 2/3 Update | |
SNG001 (IFN-β) Details Skin disease/disorder, Psoriasis | Phase 2 Update |